BTAI vs. ALLK, ORMP, PMVP, OPTN, CLSD, CUE, ANIX, IOBT, ETON, and QTTB
Should you be buying BioXcel Therapeutics stock or one of its competitors? The main competitors of BioXcel Therapeutics include Allakos (ALLK), Oramed Pharmaceuticals (ORMP), PMV Pharmaceuticals (PMVP), OptiNose (OPTN), Clearside Biomedical (CLSD), Cue Biopharma (CUE), Anixa Biosciences (ANIX), IO Biotech (IOBT), Eton Pharmaceuticals (ETON), and Q32 Bio (QTTB). These companies are all part of the "pharmaceutical preparations" industry.
BioXcel Therapeutics (NASDAQ:BTAI) and Allakos (NASDAQ:ALLK) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, institutional ownership, profitability, valuation, dividends, community ranking, earnings and risk.
BioXcel Therapeutics has a beta of 0.43, meaning that its stock price is 57% less volatile than the S&P 500. Comparatively, Allakos has a beta of 0.86, meaning that its stock price is 14% less volatile than the S&P 500.
BioXcel Therapeutics has higher revenue and earnings than Allakos. Allakos is trading at a lower price-to-earnings ratio than BioXcel Therapeutics, indicating that it is currently the more affordable of the two stocks.
30.7% of BioXcel Therapeutics shares are held by institutional investors. Comparatively, 84.6% of Allakos shares are held by institutional investors. 35.8% of BioXcel Therapeutics shares are held by insiders. Comparatively, 16.1% of Allakos shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
In the previous week, BioXcel Therapeutics and BioXcel Therapeutics both had 1 articles in the media. Allakos' average media sentiment score of 1.22 beat BioXcel Therapeutics' score of 0.00 indicating that Allakos is being referred to more favorably in the news media.
BioXcel Therapeutics presently has a consensus target price of $16.71, suggesting a potential upside of 629.88%. Allakos has a consensus target price of $1.83, suggesting a potential upside of 43.23%. Given BioXcel Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe BioXcel Therapeutics is more favorable than Allakos.
Allakos has a net margin of 0.00% compared to BioXcel Therapeutics' net margin of -12,974.86%. Allakos' return on equity of -80.23% beat BioXcel Therapeutics' return on equity.
BioXcel Therapeutics received 56 more outperform votes than Allakos when rated by MarketBeat users. Likewise, 67.14% of users gave BioXcel Therapeutics an outperform vote while only 59.34% of users gave Allakos an outperform vote.
Summary
BioXcel Therapeutics beats Allakos on 9 of the 16 factors compared between the two stocks.
Get BioXcel Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BTAI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BTAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BioXcel Therapeutics Competitors List
Related Companies and Tools
